



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Trastuzumab emtansine

<b>Cat. No.:</b>	HY-P9921
<b>CAS No.:</b>	1018448-65-1
<b>Target:</b>	EGFR; Antibody-Drug Conjugates (ADCs)
<b>Pathway:</b>	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Antibody-drug Conjugate/ADC Related
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

## Trastuzumab emtansine

### BIOLOGICAL ACTIVITY

<b>Description</b>	Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer <sup>[1][2]</sup> .
<b>In Vitro</b>	Trastuzumab emtansine (2 µg/mL; 3 d) significantly inhibits the proliferation of epithelial ovarian cancer (EOC) cells <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Trastuzumab emtansine (15 mg/kg; i.v. three to five times weekly for 3 weeks) exhibits significantly anti-tumor effect in mice <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>Animal Model:</b>	CB-17/SCID mice (6 weeks) were injected with OVA10 cells <sup>[2]</sup>
<b>Dosage:</b>	15 mg/kg
<b>Administration:</b>	I.v. three to five times weekly for 3 weeks
<b>Result:</b>	Showed remarkable inhibition of tumor growth in mice and was well tolerated.

### CUSTOMER VALIDATION

- Adv Sci (Weinh). 2024 Jan 25:e2306309.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

[1]. Verma S, et, al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783-91.

[2]. Menderes G, et, al. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA